Ad
Tuesday, 16 April 2019
Gilead teams up with insitro for experimental NASH treatments
Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment